# US 2001/0031267 A1 · Method for treatment of canine distemper

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0031267 A1
- Document ID: US20010031267A1
- Status: Published application
- Kind: A1
- Application number: 09/747,551
- Filed: 2000-12-22
- Published: 2001-10-18
- Earliest claimed: 1999-12-28
- Assignees: Milkhaus Laboratory, Inc.
- Inventors: John McMichael
- Web page: https://patentgrep.com/patent/US20010031267A1

## CPC

- A61K 39/175: Canine distemper virus
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y10S 424/818: Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to a treatment for animals having canine distemper by administering a composition comprising an attenuated canine distemper virus a sub-vaccine virus level effective to alleviate symptoms canine distemper. The invention also provides a treatment for animals having canine distemper by administering a composition comprising an attenuated canine measles virus a sub-vaccine virus level effective to alleviate symptoms canine distemper.

## Claims

### Claim 1

A method for treating a animal suffering from canine distemper comprising the step of:
administering a composition comprising an attenuated canine distemper virus at a sub-vaccine level effective to alleviate symptoms of canine distemper.

### Claim 2 (depends on 1)

The method of claim 1 wherein said composition comprises from about 10−3 TCID50 to about 500 TCID50 attenuated canine distemper virus per dose.

### Claim 3 (depends on 1)

The method of claim 1 wherein said composition comprises about 2 TCID50 attenuated canine distemper virus per dose.

### Claim 4 (depends on 1)

The method of claim 1 wherein said composition is administered to a animal in a single dose of about 0.2 cc in a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

The method of claim 1 wherein multiple daily doses of said composition are administered to the animal.

### Claim 6 (depends on 1)

The method of claim 1 where the composition is administered to a animal by a means selected from the group consisting of subcutaneously, intravenously and intramuscularly.

### Claim 7 (depends on 6)

The method of claim 6 wherein the composition is administered to a animal subcutaneously.

### Claim 8

A composition for treatment of the symptoms of canine distemper comprising an attenuated canine distemper virus at a sub-vaccine level effective to alleviate symptoms of canine distemper in a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The composition of claim 8 wherein from about 10−3 TCID50 to about 500 TCID50 attenuated canine distemper virus per dose.

### Claim 10 (depends on 9)

The composition of claim 9 which comprises 2 TCID50 attenuated canine distemper virus per dose.

### Claim 11

A method for treating a animal suffering from canine distemper comprising the step of:
administering a composition comprising an attenuated canine measles virus at a sub-vaccine level effective to alleviate symptoms of canine distemper.

### Claim 12 (depends on 11)

The method of claim 11 wherein said composition comprises from about 10−3 TCID50 to about 500 TCID50 attenuated canine measles virus per dose.

### Claim 13 (depends on 11)

The method of claim 11 wherein said composition comprises about 2 TCID50 attenuated canine measles virus per dose.

### Claim 14 (depends on 11)

The method of claim 11 wherein said composition is administered to a animal in a single dose of about 0.2 cc in a pharmaceutically acceptable carrier.

### Claim 15 (depends on 11)

The method of claim 11 wherein multiple daily doses of said composition are administered to the animal.

### Claim 16 (depends on 11)

The method of claim 11 where the composition is administered to a animal by a means selected from the group consisting of subcutaneously, intravenously and intramuscularly.

### Claim 17 (depends on 16)

The method of claim 16 wherein the composition is administered to a animal subcutaneously.

### Claim 18

A composition for treatment of the symptoms of canine distemper comprising an attenuated canine measles virus at a sub-vaccine level effective to alleviate symptoms of canine distemper in a pharmaceutically acceptable carrier.

### Claim 19 (depends on 18)

The composition of claim 18 wherein from about 10−3 TCID50 to about 500 TCID50 attenuated canine measles virus per dose.

### Claim 20 (depends on 19)

The composition of claim 19 which comprises 2 TCID50 attenuated canine measles virus per dose.
